米氮平治疗早泄106例临床观察

目的 研究米氮平(mitrazapine)治疗早泄(premature ejaculation,PE)的有效性和安全性.方法 选择门诊早泄患者106例,予以每晚口服米氮平30mg,连续使用一个月为一个疗程.治疗1～2个疗程后接受复诊或电话随访,进行疗效和安全性评估,分别记录治疗前、治疗一个疗程后阴道内射精潜伏时间(intravaginal ejaculation latency time,IELT)、治疗后性生活质量改善满意度,并详细记载药物治疗期间出现的不良反应.结果 随诊的106例PE患者,自行停药9例,其中因药物副作用不能耐受而停药的有6例(嗜热睡4例,头晕2例),其他(离异及经济因素等)原因3例.97例PE患者完整接受至少一个疗程的米氮平治疗,治疗前IELT为(1.19±0.09)min,治疗后为(4.72±2.53)min,治疗前、后差异比较,具统计学意义(P<0.001).IELT改善总有效率为68.04%,治疗后患者自我满意度达到75.26%.其他抗抑郁药物治疗无效的32例PE患者,米氮平治疗后早泄改善自我满意度调查结果满意度43.75%(14/32).结论 米氮平治疗早泄有效且安全,对于其他抗抑郁药物治疗无效的PE患者也可以尝试米氮平治疗.

Clinical efficacy of Mitrazapine in the treatment of 106 patients with premature ejaculation

Objective To explore the effectiveness and safety of Mitrazapine in treatment of patients with premature ejaculation. Methods Total of 106 patients with premature ejaculation were enrolled in the study for receiving mitrazapine treatment (30mg/day orally) for one month or two months. One or two months later, return visit or telephone follow-up was done to evaluate the effectiveness and safety, including intravaginal ejaculation latency time(IELT) before and after treatment, sexual satisfaction degree and side effects of the medicine. Results Among all tested patients, nine cases of them privately stopped treatment program, six cases of them quit treatment program for not to bear the side effects of medicine (4 cases drowsiness, 2 cases diziness) and other three cases for non-medical reasons(divorce and financial problem). Total of 97 PE patients received at least one course of Mitrazapine treatment. The average IELT of patients was (1.19±0.09) min and (4.72±2.53)min before and after treatment(P<0.001). Total IELT improving rate of them was 68.04% and self reported sexual satisfactory rate of them reached 75.26%. For 32 PE patients who were unable to get improvement with other antidepresants, after Mitrazapine treatment, their self reported sexual satisfactory rate reached 43.75%( 14/32). Conclusion Mitrazapine was a kind of effective and safe medicine in treatment of premature ejaculation. It might be a candidate drug for other antidepressants-resisting PE patients.